w abeomics

12-8460: Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP1-E2) Purified No Carrier Protein

Clonality :	Monoclonal
Clone Name :	NP1-E2
Application :	ELISA
Alternative Name	COV2-NP1-E2, SARS-CoV-2 Nucleocapsid, SARS-CoV-2 Nucleoprotein, Protein N, SARS-CoV N Protein
lsotype :	Human IgG1

Description

Specificity: Anti-SARS-CoV-2 Nucleocapsid, clone NP1-E2, specifically targets an epitope on the SARS-CoV-2 nucleocapsid protein. Furthermore, it is reported to bind to the RNA binding domain of the N protein.

Antigen Distribution: The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2.

Background: Coronavirus disease 2019 (COVID-19) is caused by the Coronaviridae family virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1. SARS-CoV-2 has four structural proteins encoded by its single-stranded, positive-sense RNA genome: the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins2. The N protein is a highly conserved 46 kDa protein that shares 90% homology with SARS-CoV3. The N protein has an N-terminal (NTD) and C-terminal domain (CTD), which bind to RNA and self-oligomerize, respectively4,5, forming a helical nucleocapsid structure within the viral envelope6. Other functions of the N protein included viral transcription, replication, and modulating cell signaling pathways7,8. The N protein is abundantly expressed during infection, and antibodies3,9 and memory T cells10,11 targeting the N protein have been identified in convalescent sera. Therefore, the N protein is a target in some vaccines and diagnostic assays12. The N protein also has therapeutic potential, as it evades RNAi-mediated antiviral responses13.

Product Info 100 µg / 500 µg Amount : Purity :>=90% monomer by analytical SEC and SDS-Page Preparation : Recombinant antibodies are manufactured in an animal free facility using only in **Purification**: vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Concentration:>=1.0 mg/ml Formulation: This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, Content : potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term Storage condition : storage, aseptically aliquot in working volumes without diluting and store at <= -70°C.?Avoid Repeated Freeze Thaw Cycles.